William Go, M.D., Ph.D.
Chief Development Officer of BioMarin
William Go, M.D., Ph.D., is currently the Chief Development Officer of BioMarin. Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of genetic conditions. BioMarin discoveries have led to eight first or best-in-class commercial treatments and a pipeline of multiple products in development. Will leads and drives all development functions to advance BioMarin’s promising portfolio of new medicines in genetic defined conditions.
Prior to BioMarin, Will was the Chief Medical Officer at A2 Bio, overseeing all aspects of A2 Bio’s development of T cell therapies utilizing the company’s novel logic-gated CAR T platform focused on curing solid tumor cancers. A2 Bio has raised over 350 million dollars with 3 successful novel CAR T-cell Investigational New Drug applications leading to the establishment of 3 Phase 1 studies in 3 years in Pancreatic, Colorectal, Lung, Breast, Ovarian and many other solid tumor cancers.
Previously, Will worked at Kite Pharma (acquired by Gilead) where he developed novel immune-cellular therapies for the treatment of cancer. At Kite, Will led the ZUMA-1 pivotal study and eventual FDA and EMA approvals of YESCARTA®, the first CAR T cell therapy approved in large B-cell Lymphoma. YESCARTA received the Prix Galien Award for Best Biotechnology Product in 2018. He became a vice president of clinical development at Kite/Gilead leading large B-cell lymphoma clinical development.
Earlier in his career, Will played an instrumental role in the clinical development of Vectibix® in colorectal cancer, as well as identifying new predictive biomarkers as a medical director in global clinical development at Amgen.
Will received his bachelor’s degree in biology from Carleton College and then attended the University of California San Diego’s (UCSD) Medical Scientist Training Program (MSTP). He received his Ph.D. in Biomedical Sciences (BMS) in 2004 with a focus on immunology and completed his M.D. in 2006. Will did his internal medicine residency, hematology/oncology fellowship at UCSD School of Medicine and the UCSD Moores Cancer Center respectively. He was the recipient of the California Institute for Regenerative Medicine (CIRM) fellowship award and the American Association of Cancer Institutes’ (AACI) fellowship award studying tumor immunology.